Libtayo Cleared for Frontline Use in Advanced NSCLC With High PD-L1 Expression
The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial.
The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial.
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).